Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report

Acta Oncologica

Volumn 44, Issue 3, 2005, Pages 203-217

  Nygren, Peter ^a   Sørbye, Halfdan ^b   Österlund, Pia ^c   Pfeiffer, Per ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOZYME; ANTIMETASTATIC AGENT; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN; CAPECITABINE; CELECOXIB; CETUXIMAB; CGP 69846A; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; INDISULAM; IRINOTECAN; ISIS 3521; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; MONOCLONAL ANTIBODY; ONYX 015; OXALIPLATIN; PANITUMUMAB; PELITINIB; SU 55416; TIPIFARNIB; TRASTUZUMAB; TROGLITAZONE; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; EPISTAXIS; GENE TARGETING; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTESTINE PERFORATION; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOSIS; VOMITING; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 21344432989     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860510029798     Document Type: Review

References (96)

1. The Meta-analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22: 3766-75.
2. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of 5-FU/Lvuorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
3. De Gramont A, Bosset JF, Milan C, Rouqier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and 5-FU/Lvuorouracil bolus plus continuous infusion for advanced colorectal cancer: an French intergroup study. J Clin Oncol 1997;15:808-15.
4. Ragnhammar P, Hafström L, Nygren P, Glimelius B. A systemativ overview of chemotherapy effects in colorectal cancer. Acta Oncol 2001;40:282-308.
5. Punt C. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15:1453-9.
6. Köhne C-H, Folprecht G. Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol 2004; 15:iv43-53.
7. Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22: 1209-14.
8. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magné N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol 2004;15:1007-12.
9. Tabernero J, Salazar R, Casado E, Martinelli E, Gómez P, Baselga J. Targeted therapy in advanced colon cancer: the role of new therapies. Ann Oncol 2004;15:iv55-62.
10. Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of becacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Disc 2004;3:391-400.
11. Nygren P, Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Internal Med 2003;253: 46-75.
12. Sobrero A, Guglielmi A. Current controversies in the adjuvant therapy of colon cancer. Ann Oncol 2004;15: iv39-41.
13. Sobrero AF. Scheduling of fluorouracil: a forget-me-not in the jungle of doublets. J Clin Oncol 2004;22:4-6.
14. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta analysis. Br Med J 2000;321:531-5.
15. Könne C-H, Wils J, Lorenz M, Schöttski P, Voigtmann R, Bokemeyer C, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour inufsion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-8.
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moree MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 2000;343: 905-14.
17. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek JP, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet 2000;355:1041-7.
18. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
19. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
20. Glimelius B, Jakobsen A, Graf W, Berglund Å, Gadeberg C, Hansen P, et al. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Eur J Cancer 1998;34:674-8.
21. Sörbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, et al. Multicenter phase II study of nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004;22:31-8.
22. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
23. Hoff PM, Ansari R, Batist G, Cox JV, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
24. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. Xelox (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
25. Arkenau HT, Kubicka S, Grall R, Seufferlein T, Freier W, Graeven U, et al. Phase III trial of infusional 5-fluorouracil/ folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of advanced colorectal carcinoma: results of an interim efficacy and safety analysis. 2004 ESMO Meeting; A 272PD.
26. De Gramont A, Figer A, Seymou M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
27. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolu R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
28. Schilsky RL. First-line treatment options for patients with metastatic colorectal cancer. Nature Clin Pract Oncol 2004; 1:70-1.
29. Glimelius B, Ristamäki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit KM, et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002;13:1868-73.
30. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labiamca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet 1998;352:1407-12.
31. Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal cancer. J Clin Oncol 2004;22:2078-83.
32. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of iriontecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet 1998;352:1413-8.
33. Willer AM, Hofheinz RD, Wein A, Gnad-Vogt U, Saussele S, Hehlmann R, et al. A phase II trial of second-line irinotecan and capecitabine after failure of first-line infusional 5-5-FU/ Lvuorouracil and folinic acid in metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2004;23:A3752.
34. André T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, et al. Multicenter phase II study of bimontly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17: 3560-8.
35. Rothenberg M, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-69.
36. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004;22:4753-61.
37. Pfeiffer P, Hahn P, Jensen HA. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. Acta Oncol 2003;42:832-6.
38. Popov I, Jelic SB, Radosavljevic DI, Tomaseciv ZZ, Jezdic SD. Which one is the best sequence of chemotherapy administration in advanced colorectal cancer? Results of five arms single centre study. 2004 ESMO Meeting; A 302P.
39. Glimelius B. Palliative treatment of patients with colorectal cancer. Scand J Surg 2003;92:74-83.
40. Burkart C, Budach W, Hartmann JT, Klump B, Pereira P, Teichman R, et al. Outcome of patients with metastatic or locally advanced unresectable colorectal cancer in routine care. 2004 ESMO Meeting; A 354P.
41. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
42. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
43. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting AST, Segnaeve C, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 1991;64:361-4.
44. Linn SC, van Kalken CK, van Tellingen O, van der Kalk P, van Groeningen CJ, Kuiper CM, et al. Clinical and pharmacological study of multidrug resistance reversal with vinblastine and bepridil. J Clin Oncol 1994;12:812-9.
45. Mainwaring PN, Van Cutsem E, Van Laethem J-L, Propper D, Twelves C, Bridgewater J, et al. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Annual Meeting of the American Society of Clinical Oncology 2002;21:A611.
46. Rao S, Cunningham D, De Gramont A, Scheithauer W, Smakal M, Humblet Y, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22:3950-7.
47. Sharma S, Kemeny N, Kelsen DP, Jison D, O'Reilly E, Zaknoen S, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refrectory to 5-fluorouracil and irinotecan. Ann Oncol 2002; 13:1067-71.
48. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br J Cancer 2004;91:418-24.
49. Fischer GA, Kuo T, Cho CD, Halsey J, Jambolos CN, Schwartz EJ, et al. A phase II study of gefitinib in combination with FOLFOX-4 in patients with metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2004;23:A3514.
50. Oza AM, Townsley CA, Siu LL, Major P, Hedley D, Tsao M, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2003;22:A785.
51. Casado E, Folprecht G, Paz Ares L, Rojo J, Köhne CH, Cortes-Funes H, et al. A phase I/IIA pharmacokinetic and serial skin and tumour pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) regimen in patients with advanced colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2004;23:A3543.
52. Mackay HJ, Major P, Townsley CA, Mackenzie M, Vincent M, Pond G, et al. A phase II trial of the proteosome inhibitor PS-341 (bortezomib; Velcade) in patients with metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2004;23:A264.
53. Cripps MC, Figueredo AT, Oza AM, Taylor MJ, Fields AJ, Holmlund JT, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group study. Clin Cancer Res 2002;8:2188-92.
54. Köhne C-H, Dubois RN. Cox-2 inhibition and colorectal cancer. Semin Oncol 2004;21:12-21.
55. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Eng J Med 2004;351:337-45.
56. Meropol NJ, Berlin J, Hecht JR, Croghan GA, Patnaik A, Weiner LM, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2003; 22:A1026.
57. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004;40:1292-301.
58. Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, et al. Low expression of Her-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan therapy. A phase II trial. Cancer Invest 2004;22:858-65.
59. Kerr D. Clinical development of gene therapy for colorectal cancer. Nature Rev Cancer 2003;3:615-22.
60. King J, Zhao J, Clingan P, Morris DG. Randomised double blind placebo controlled study of adjunvant treatment with the metolloproteinase inhibitor marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculosceletal side-effects. Anticancer Res 2003;23:639-45.
61. Kulke MH, Demetri GD, Sharpless NE, Shivdasani R, Clark JS, Eder JP, et al. A phase II study of troglitazone, an activator of PPAR-gamma, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002;8:395-9.
62. Zonder JA, Shields AF, Zalupski M, Chaplen R, Heilbrun LK, Arlau P, et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res 2001;7:38-42.
63. Guba M, Seeliger H, Kleespies A, Jauch K-W, Bruns C. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 2004;19:510-7.
64. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan,- fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004;350:2335-42.
65. Steward WP, Thomas AL, Morgan B, Wiedenmann B, Bartel C, Vanhoeter U, et al. Extended phase I study of the oral vascular endothelial growth factor receptor inhibitor PTK/ZK 222584 in combination with oxaliplatin/5-fluorouracil/ leucovorin as first line treatment for metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2003;22:A1098.
66. Venook A, Hurwitz H, Cunningham C, Burris HA, Aitchison R, Radka J, et al. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: results of a phase II trial of a ribozyme targeting the pre-mRNA for VEGFR-1 (angiozyme), in combination with chemotherapy. Annual meeting of the American Society of Clinical Oncology 2003;22:A1025.
67. Hicklin DJ, Elllis LM. Role of the vascular endothelial growth factor pathaway in tumour growth and angiogenesis. J Clin Oncol 2005;23:Published ahead of print.
68. Willet CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Medicine 2004;10:145-7.
69. Maxwell-Armstrong CA, Durrant LG, Buckley TJ, Scholefield JH, Robins RA, Fielding K, et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001, 84:1433-6.
70. Hamid O, Varterasian ML, Wadler S, Benson III AB, Galanis E, Uprichard M, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:1498-504.
71. Harris M. Monoclonal antibodies as therapeutic agents for cancer. The Lancet Oncol 2004;5:292-302.
72. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Leiberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
73. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht R, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:Published ahead of print.
74. Hedrick E, Hurwitz H, Sarkar S, Griffing S, Grothey A. Impact of post-progression therapy on survival in AVF2107, a phase III trial of bevacizumab in the first -line treatment of metastatic colorectal cancer. 2004 ESMO Meeting; A 357P.
75. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
76. Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth JJ, Heim W, et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Annual meeting of the American Society of Clinical Oncology 2004;23:A3617.
77. Hambleton J, Novotny WF, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Annual meeting of the American Society of Clinical Oncology 2004;23: A3528.
78. Scappaticci F, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery. Annual meeting of the American Society of Clinical Oncology 2004;23:A3530.
79. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. Annual Meeting of the American Society of Clinical Oncology 2004;23:A3702.
80. Novotny W, Holmgren E, Nelson B, Mass R, Kabbinavar F, Hurwitz H. Bevacizumab does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer. Annual meeting of the American Society of Clinical Oncology 2004;23:A3529.
81. Chen HX, Mooney M, Boron M, Grochow L, Zwiebel J, Vena D, et al. Bevacizumab (BV) plus 5-FU/leucovorin for advanced colorectal cancer that progressed after standard chemotherapies: an NCI treatment referral center trial (TRC-0301). Annual meeting of the American Society of Clinical Oncology 2004;23:A3515.
82. Giantonio BJ, Catalano PJ, Meropol NJ, O'Duyer PJ, Mitchell EP, Alberts SR, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. 2005 Gastrointestinal Cancers Symposium 2005; A 169a.
83. Saltz LB, Lenz HJ, Kindler H, Hochster H, Wadler S, Hoff P, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/ bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2005 Gastrointestinal Cancers Symposium 2005; A 169b.
84. Folprecht G, Lutz M, Schoeffski P, Seufterlein T, Haag C, Beutel G, et al. Cetuximab/irinotecan/high-dose-5-fluorouracil/leucovorin in the first-line therapy of metastatic colorectal cancer. Gastrointestinal Cancers Symposium 2004; A 283.
85. Van Cutsem EJD, Tabernero J, Diaz-Rubio E, Chirivella I, André T, Humblet Y, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil/ folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). 2004 ESMO Meeting; A 339P.
86. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
87. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab plus irinotecan is active in irinotecan refractory colorectal cancer that expresses epidermal growth factor receptor. Annual meeting of the American Society of Clinical Oncology 2001;19:A7.
88. Lenz HJ, Mayer RJ, Gold PJ, Mirtsching B, Stella PJ, Cohn AL, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Annual meeting of the American Society of Clinical Oncology 2004; 23:A3510.
89. Chung KY, Shia J, Kemeny NE, Shah M, Schwatz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumours that do not express the epidermal growth factor by immunohistochemistry. J Clin Oncol 2005;23:Published ahead of print.
90. Meropol NJ. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. J Clin Oncol 2005;23:Published ahead of print.
91. Norsk Offentlig Utredning 1997:2, Minimumsbehandlingseffekter i kreftbehandling. 8.1.2.2.
92. Ragnhammar P, Brorsson B, Nygren P, Glimelius B. A prospective study of the use of chemotherapy in Sweden and assessment of the use in relation to scientific evidence. Acta Oncol 2001;40:391-411.
93. Miller LL, Elfring GL, Gruia G, Hirawat S, Douillard JY, Saltz LB. A case for time to tumour progression as the primary efficacy endpoint in 1st-line m metastatic colorectal cancer: correlation of TTP and overall survival. Annual meeting of the American Society of Clinical Oncology 2004; 23:A3503.
94. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Eng J Med 2004;351:317-9.
95. Folprecht G, Cunningham D, Ross P, Glimelius B, Di Constanze F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15:1330-8.
96. Sobrero A, Bruzzi P. Bevacuzumab plus fluorouracil: the value of being part of a developing story. J Clin Oncol 2005;23:Published ahead of print.